- Home
- MOLN vs SGMT Comparison
MOLN vs SGMT Comparison
Compare MOLN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MOLN | SGMT |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.2M | 169.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MOLN | SGMT |
|---|---|---|
| Price | $4.12 | $8.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $8.38 | ★ $26.13 |
| AVG Volume (30 Days) | 1.1K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $374.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.46 | $4.50 |
| 52 Week High | $5.36 | $10.06 |
Technical Indicators
Market Signals| Indicator | MOLN | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 52.06 | 68.49 |
| Support Level | $3.94 | $6.95 |
| Resistance Level | $4.13 | $8.84 |
| Average True Range (ATR) | 0.07 | 0.50 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 62.28 | 90.51 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.